Last reviewed · How we verify
L-ornithine-L-aspartate and lactulose
L-ornithine-L-aspartate and lactulose is a Small molecule drug developed by Mahidol University. It is currently FDA-approved.
L-ornithine-L-aspartate and lactulose, marketed by Mahidol University, holds a niche position in the pharmaceutical market with its unique combination therapy. The key composition patent expires in 2028, providing a significant period of exclusivity and potential revenue protection. However, the lack of detailed clinical trial results and revenue data poses a primary risk, limiting the drug's visibility and market appeal.
At a glance
| Generic name | L-ornithine-L-aspartate and lactulose |
|---|---|
| Sponsor | Mahidol University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (NA)
- A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. (PHASE4)
- Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy (PHASE4)
- Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment (NA)
- Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-ornithine-L-aspartate and lactulose CI brief — competitive landscape report
- L-ornithine-L-aspartate and lactulose updates RSS · CI watch RSS
- Mahidol University portfolio CI